ISSN: 2332-0877

Journal des maladies infectieuses et de la thérapie

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Application of a Protease Inhibitor for the Treatment of Viral Respiratory Infections: Acceptable Concentrations of the Protease Inhibitor Nafamostat and Ammonium Chloride for Direct Administration to the Respiratory Epithelium of Mice

Satoko Nakagomi

Back ground: Enveloped viruses invade cells by fusing the viral envelope with the cell membrane. Most viral fusion proteins require specific host protease(s) to activate their fusion activity. Many influenza viruses and severe acute respiratory syndrome associated coronaviruses use transmembrane serine protease TMPRSS2 for activation. Protease inhibitor nafamostat suppresses TMPRSS2, thereby interfering with the viral infection in-vitro. However, no successful application of nafamostat for the treatment of respiratory viral infection has been reported. This is because no method has been established to deliver nafamostat to the respiratory epithelium. Additionally, many coronaviruses have another infectious pathway, in which the virus is engulfed in endosome and activated by endosomal protease(s) and acidification. Ammonium chloride is known to block this pathway in-vitro , by interfering with the endosomal acidification. The present study has done to explore the method to safely deliver these reagents by assessing whether adverse effects occur when the reagents are administered to the respiratory epithelium in mice.

Methods: To ass ess adverse effects, inbred mice were intranasally administered the reagents 2~20 μL/day for a week under anesthesia. Mice were daily observed and change in the body weight was used as a health status barometer. At the end of experiment, the serum biochemical examination was done.

Results: The solution of 200 μM nafamostat and 74 mM ammonium chloride could be intranasally administered 20 μL/day for 1 week to adult C57BL/6 mice without any visible adverse effects. Biochemical data on these mice were within the normal range.

Conclusion: Since 1 μM nafamostat and 50 mM ammonium chloride are known to efficiently suppress the viral invasion to cell in-vitro, nafamostat is highly expected to show inhibitory effect in the virus-infected mice, and ammonium chloride may be also available to treat the virus-infected mice. The present study encourages future researches in infected mice and to apply these reagents for the clinical treatment.